BCL2 and non-small cell lung carcinoma: As an example, one study in non-small lung cell cancers showed that drug-resistant tumor cells with acquired resistance conferred by the EGFRT790M mutation could be re-sensitized to EGFR TKIs by co-targeting them with navitoclax, an inhibitor of BCL-2 and BCL-XL (180).